Full Fed. Circ. Won't Consider Standing In Novartis Drug Case
By Hailey Konnath ( July 9, 2020, 10:58 PM EDT) -- The full Federal Circuit on Thursday declined to review a three-judge panel's April opinion finding that Argentum Pharmaceuticals lacked standing to appeal a Patent Trial and Appeal Board decision upholding the validity of a patent covering Novartis' multiple sclerosis drug, rejecting Argentum's petition for rehearing en banc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.